Market news

QTTB stock outlook: bempikibart may deliver lasting alopecia areata hair regrowth; financing reduces near-term risk.

The heavy selling pressure might have exhausted for Q32 Bio (QTTB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

The average of price targets set by Wall Street analysts indicates a potential upside of 182.2% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended June 30, 2026, and provided recent corporate updates.

The consensus price target hints at an 186% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Q32 Bio (QTTB) have what it takes to be a top stock pick for momentum investors? Let's find out.

The consensus price target hints at an 80.1% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Q32 Bio (QTTB) stock slips after pricing a $200M public offering at $18.25. Get the details on the deal and share reaction.

Q32 Bio (QTTB) is back in focus after reporting positive 36 week topline data from Part B of its Phase 2a SIGNAL AA trial of bempikibart in severe alopecia areata. See our latest analysis for Q32 Bio. Q32 Bio’s latest clinical update has arrived alongside sharp share price moves, with a 1-day share price return of 90.72% and 90-day share price return of 263.61%, contributing to a very large 1-year total shareholder return off a low base. The current share price of $21.38 and recent follow on...

Q32 Bio (NASDAQ:QTTB) has outperformed the market over the past 5 years by 11.82% on an annualized basis producing an average annual return of 23.91%. Currently, Q32 Bio has a market capitalization of $317.42 million.

Investors backed strong catalysts, including analyst upgrades, biotech trial results and improving freight outlooks.

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA. Bempikibart is a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling

Q32 Bio (NASDAQ:QTTB) reported positive 36-week top-line results from Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata, a disease that causes hair loss and can carry a significant psychosocial burden. President and Chief

Q32 Bio reported positive Phase 2a data for bempikibart in severe alopecia areata, showing hair regrowth and favorable safety.

Phase 2 Data Boosts Investor ConfidenceQ32 Bio Inc. (NASDAQ:QTTB) shares surged 60% on Monday after the biotechnology company announced positive topline results from the 36-week Part B analysis of its SIGNAL-AA Phase 2a study evaluating bempikibart for the treatment of severe and very severe alopecia areata.

Patients treated with bempikibart for 36 weeks saw a 35% average reduction in scalp hair loss severity, the company said.

The biotech is advancing a potential treatment for a common autoimmune disease.

Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-market session. The company's market cap stands at $213.4 million. China Pharma Holding (AMEX:CPHI) shares increased